The FDA asked Cytokinetics for the Risk Evaluation and Mitigation Strategy after it had already accepted the application for aficamten, a potential competitor to Bristol Myers Squibbs heart drug Camzyos. Analysts say this development could signal a change in FDA thinking about risk management for the broader drug class. The post FDA Pushes Out Decision…
AI addresses the disconnect between recommended guidelines and action by increasing engagement with personalized, actionable education and updates at appropriate times, The post AI in Clinical Settings: Balancing Innovation, Patient Care, and Personalized Medicine appeared first on MedCity News.
As healthcare costs continue to rise, three data-driven strategies can help companies reduce the expense of employee health benefits – without sacrificing quality. The post 3 Ways Companies Can Make Healthcare More Affordable appeared first on MedCity News.
MedCity INVEST is a boutique healthcare investor conference scheduled for May 20-21 at the Willis Tower in Chicago. Register today! The post Time is Running Out to Join the Healthcare Innovation Conversation at INVEST 2025 appeared first on MedCity News.
An analysis by Axene Health Partners revealed that Imagine360 delivered 19% in annual savings—equating to $7.7 million—compared to traditional health plans for Rollins, a pest control company. The post How Imagine360 Saved this Employer 19% Compared to Traditional Health Plans appeared first on MedCity News.
German medical device company seca released the first portable body composition scanner designed for primary care. The scanner seeks to give primary care providers a more accurate picture of their patient’s health, as well as help them spot certain conditions — such as sarcopenia, obesity and metabolic disorders — earlier. The post Seca Launches First…
United Healthcare’s shocking quarterly earnings miss, a new regular feature on the Trump administration’s healthcare moves, and the future of value-based care. That’s the focus of the latest episode of the Debunked podcast with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. The post Debunked Episode 15: How Did…
Johnson & Johnson’s Imaavy is now FDA-approved for treating generalized myasthenia gravis, introducing competition to Argenx and UCB drugs that treat this rare neuromuscular disorder. J&J is also developing its new drug for other diseases and projects it could reach $5 billion in peak sales across multiple rare and prevalent conditions. The post FDA Nod…
ICHRA is surging in popularity as an option for employer-sponsored insurance to access the individual market, as employers rethink traditional group plans with unpredictable renewal rates and employees seek personalized healthcare. Here’s a closer look at why investors and politicians are eyeing ICHRA. The post The ICHRA Moment Is Here — Are You Ready for It?…
The opioid settlement funds provide a crucial opportunity to get increased state or municipal funding behind mail-based naloxone delivery. Through partnering with existing organizations that already have robust infrastructure in place and substantial experience in mail-based naloxone municipalities can scale efforts efficiently. The post Expanding Support for Mail-Based Naloxone Delivery appeared first on MedCity News.